4//SEC Filing
Erlander Mark 4
Accession 0001628280-21-000060
CIK 0001213037other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:03 PM ET
Size
9.3 KB
Accession
0001628280-21-000060
Insider Transaction Report
Form 4
Erlander Mark
DirectorChief Executive Officer
Transactions
- Tax Payment
Common Stock
2021-01-02−113→ 13,516 total - Exercise/Conversion
Common Stock
2021-01-02+260→ 13,629 total - Exercise/Conversion
Restricted Stock Units
2021-01-02−260→ 0 total→ Common Stock (260 underlying)
Footnotes (4)
- [F1]Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017.
- [F2]The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021.
- [F3]Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock.
- [F4]On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4.
Documents
Issuer
Cardiff Oncology, Inc.
CIK 0001213037
Entity typeother
Related Parties
1- filerCIK 0001651537
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:03 PM ET
- Size
- 9.3 KB